Acadian Asset Management
ONCE

Acadian Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Acadian Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-115
Closed -$6K – 1911
2018
Q3 		$6K Buy
+115
New +$7.86K ﹤0.01% 1618

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management's ONCE Position: Q4 2018 in Review

Acadian Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 115 shares — an estimated $6K sold.

Acadian Asset Management first reported a position in ONCE in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Acadian Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Acadian Asset Management sold 115 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $6K.
  • Acadian Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Acadian Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $6K in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Acadian Asset Management's 13F filing for Q4 2018, filed 7 Feb 2019.